We are live on ! Find out more
BNTX icon

BioNTech

303 hedge funds and large institutions have $5.73B invested in BioNTech in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 84 increasing their positions, 88 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more capital inflows, than outflows

Capital inflows: $797M | Capital outflows: $455M

39% more call options, than puts

Call options by funds: $373M | Put options by funds: $269M

3% more funds holding

Funds holding: 295 → 303 (+8)

2.58% more ownership

Funds ownership: 18.39% → 20.98% (+2.6%)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

5% less repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 88

8% less first-time investments, than exits

New positions opened: 44 | Existing positions closed: 48

Holders
303
Holders Change
+8
Holders Change %
+2.71%
% of All Funds
3.98%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
44
Increased
84
Reduced
88
Closed
48
Calls
$373​M
Puts
$269​M
Net Calls
+$104​M
Net Calls Change
+$54​M

BNTX Hedge Fund Activity: Q4 2024 in Review

303 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q4 2024, worth a combined $5.73B — up 11% from $5.18B a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of BNTX and 44 opened new positions — a net loss of 4 holders — while 88 trimmed existing stakes and 84 added.

The largest buyer was Fidelity Investments, adding an estimated $160M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $73.7M sold.

  • 303 institutional investors held BioNTech (BNTX) as of Q4 2024, up from 295 in Q3 2024.
  • Funds reported $5.73B of BioNTech stock for Q4 2024, up 11% quarter-over-quarter.
  • 44 funds opened new BioNTech positions in Q4 2024 and 48 closed out, a net change of -4 holders.
  • The largest BioNTech buyer in Q4 2024 was Fidelity Investments, an estimated $160M added.
  • The largest BioNTech seller in Q4 2024 was Balyasny Asset Management, an estimated $73.7M sold.

Based on aggregated 13F filings for Q4 2024.